Vaxcyte Inc. (PCVX)
Vaxcyte Statistics
Share Statistics
Vaxcyte has 128.76M shares outstanding. The number of shares has increased by 14.97% in one year.
| Shares Outstanding | 128.76M |
| Shares Change (YoY) | 14.97% |
| Shares Change (QoQ) | 2.33% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 125.07M |
| Failed to Deliver (FTD) Shares | 76 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 14.49M, so 11.62% of the outstanding shares have been sold short.
| Short Interest | 14.49M |
| Short % of Shares Out | 11.62% |
| Short % of Float | 12.04% |
| Short Ratio (days to cover) | 12.34 |
Valuation Ratios
The PE ratio is -21.53 and the forward PE ratio is -21.19. Vaxcyte's PEG ratio is 2.62.
| PE Ratio | -21.53 |
| Forward PE | -21.19 |
| PS Ratio | 0 |
| Forward PS | 2.9 |
| PB Ratio | 3.02 |
| P/FCF Ratio | -21.02 |
| PEG Ratio | 2.62 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vaxcyte Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.75, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.75 |
| Quick Ratio | 12.75 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.11 |
| Cash Flow / Debt | -6.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.14% and return on capital (ROIC) is -16.87%.
| Return on Equity (ROE) | -0.14% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -16.87% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,120,596.62 |
| Employee Count | 414 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.65% in the last 52 weeks. The beta is 1.02, so Vaxcyte's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -44.65% |
| 50-Day Moving Average | 80.14 |
| 200-Day Moving Average | 89.24 |
| Relative Strength Index (RSI) | 37.8 |
| Average Volume (20 Days) | 1.14M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -569.55M |
| Net Income | -463.93M |
| EBITDA | -569.55M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.8 |
Balance Sheet
The company has 387.88M in cash and 71.11M in debt, giving a net cash position of 316.77M.
| Cash & Cash Equivalents | 387.88M |
| Total Debt | 71.11M |
| Net Cash | 316.77M |
| Retained Earnings | -1.39B |
| Total Assets | 3.51B |
| Working Capital | 1.65B |
Cash Flow
In the last 12 months, operating cash flow was -452.63M and capital expenditures -22.43M, giving a free cash flow of -475.05M.
| Operating Cash Flow | -452.63M |
| Capital Expenditures | -22.43M |
| Free Cash Flow | -475.05M |
| FCF Per Share | -3.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PCVX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.05% |
| FCF Yield | -9.76% |
Analyst Forecast
The average price target for PCVX is $146.5, which is 287.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $146.5 |
| Price Target Difference | 287.5% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 26.05 |
| Piotroski F-Score | 2 |